GLUCAGON Drug Patent Profile
✉ Email this page to a colleague
When do Glucagon patents expire, and when can generic versions of Glucagon launch?
Glucagon is a drug marketed by Amphastar Pharms Inc, Lilly, and Fresenius Kabi Usa. and is included in four NDAs.
The generic ingredient in GLUCAGON is glucagon hydrochloride. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the glucagon hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for GLUCAGON?
- What are the global sales for GLUCAGON?
- What is Average Wholesale Price for GLUCAGON?
Summary for GLUCAGON
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 4 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 27 |
| Clinical Trials: | 823 |
| Drug Prices: | Drug price information for GLUCAGON |
| What excipients (inactive ingredients) are in GLUCAGON? | GLUCAGON excipients list |
| DailyMed Link: | GLUCAGON at DailyMed |
Recent Clinical Trials for GLUCAGON
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pichamol Jirapinyo, MD, MPH | Phase 4 |
| National Center for Advancing Translational Sciences (NCATS) | Early Phase 1 |
| Ain Shams University | N/A |
Pharmacology for GLUCAGON
Medical Subject Heading (MeSH) Categories for GLUCAGON
Anatomical Therapeutic Chemical (ATC) Classes for GLUCAGON
US Patents and Regulatory Information for GLUCAGON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amphastar Pharms Inc | GLUCAGON | glucagon | INJECTABLE;INJECTION | 208086-001 | Dec 28, 2020 | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lilly | GLUCAGON | glucagon hydrochloride | INJECTABLE;INJECTION | 012122-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lilly | GLUCAGON | glucagon hydrochloride | INJECTABLE;INJECTION | 012122-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lilly | GLUCAGON | glucagon | INJECTABLE;INJECTION | 020928-001 | Sep 11, 1998 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Fresenius Kabi Usa | GLUCAGON | glucagon hydrochloride | POWDER;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 201849-002 | Sep 19, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Fresenius Kabi Usa | GLUCAGON | glucagon hydrochloride | POWDER;INTRAMUSCULAR, INTRAVENOUS | 201849-001 | May 8, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for GLUCAGON
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Tetris Pharma B.V | Ogluo | glucagon | EMEA/H/C/005391 Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. |
Authorised | no | no | no | 2021-02-11 | |
| Eli Lilly Nederland B.V. | Baqsimi | glucagon | EMEA/H/C/003848 Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus. |
Authorised | no | no | no | 2019-12-16 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
